Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment.
The results validate claims that the technique can deliver higher quality nerve repair, compared to existing methods.
Results also showed the use of CelGro in rats restored nerve fibres to complete regeneration, with these being indistinguishable from normal nerve histology.
Price: 0.535 AUD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US....
Industry & services
